Monoamine transporter and receptor interaction profiles of a new series of designer cathinones

Neuropharmacology

Volumn 79, Issue , 2014, Pages 152-160

  Simmler, L D ^a   Rickli, A ^a   Hoener, M C ^b   Liechti, M E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Bath salts; Dopamine; Norepinephrine; Serotonin; Transporter

Indexed keywords

3 FLUOROMETHCATHINONE; 3,4 METHYLENEDIOXYMETHAMPHETAMINE; 4 METHYLETHCATHINONE; 4 METHYLTHIOAMPHETAMINE; ALPHA ADRENERGIC RECEPTOR; BUPHEDRONE; CATHINONE; CITALOPRAM; DOPAMINE; DOPAMINE RECEPTOR; DOPAMINE TRANSPORTER; ETHCATHINONE; HISTAMINE H1 RECEPTOR; MAZINDOL; METHAMPHETAMINE; METHEDRONE; N ETHYLAMPHETAMINE; N METHYL 1 (4 METHOXYPHENYL) 2 AMINOPROPANE; N,N DIMETHYLCATHINONE; NISOXETINE; NORADRENALIN; NORADRENALIN TRANSPORTER; PARAMETHOXYAMPHETAMINE; PENTEDRONE; PENTYLONE; SEROTONIN; SEROTONIN RECEPTOR; SEROTONIN TRANSPORTER; TRACE AMINE ASSOCIATED RECEPTOR 1; UNCLASSIFIED DRUG; 2-ETHYLAMINO-1-PHENYL-PROPAN-1-ONE; 3-FLUOROMETHCATHINONE; 4-METHOXYMETHCATHINONE; 4-METHYLETHCATHINONE; ADRENERGIC RECEPTOR AFFECTING AGENT; ALKANONE; AMPHETAMINE DERIVATIVE; BIOGENIC AMINE; BUTYROPHENONE DERIVATIVE; DESIGNER DRUG; DOPAMINE UPTAKE INHIBITOR; METHYLAMINE; N,N-DIMETHYLCATHINONE; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORTER; PROPIOPHENONE DERIVATIVE; RECEPTOR; SEROTONIN UPTAKE INHIBITOR;

ARTICLE; BINDING AFFINITY; CELL STRAIN HEK293; CONTROLLED STUDY; DRUG RECEPTOR BINDING; HUMAN; HUMAN CELL; MONOAMINE METABOLISM; MONOAMINE RELEASE; MONOAMINE UPTAKE TRANSPORTER INHIBITION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; RECEPTOR BINDING; ANTAGONISTS AND INHIBITORS; HEK293 CELL LINE; METABOLISM;

ADRENERGIC UPTAKE INHIBITORS; AMPHETAMINES; BIOGENIC MONOAMINES; BUTYROPHENONES; DESIGNER DRUGS; DOPAMINE UPTAKE INHIBITORS; HEK293 CELLS; HUMANS; METHYLAMINES; PENTANONES; PLASMA MEMBRANE NEUROTRANSMITTER TRANSPORT PROTEINS; PROPIOPHENONES; RECEPTORS, BIOGENIC AMINE; SEROTONIN UPTAKE INHIBITORS;

EID: 84890111184     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2013.11.008     Document Type: Article

References (66)

1. S.M. Aarde, P.K. Huang, K.M. Creehan, T.J. Dickerson, and M.A. Taffe The novel recreational drug 3,4-methylenedioxypyrovalerone (MDPV) is a potent psychomotor stimulant: self-administration and locomotor activity in rats Neuropharmacology 71 2013 130 140
2. R.P. Archer Fluoromethcathinone, a new substance of abuse Forens. Sci. Int. 185 2009 10 20
3. C.T. Bauer, M.L. Banks, B.E. Blough, and S.S. Negus Use of intracranial self-stimulation to evaluate abuse-related and abuse-limiting effects of monoamine releasers in rats Br. J. Pharmacol. 168 2013 850 862
4. M.H. Baumann, M.A. Ayestas Jr., J.S. Partilla, J.R. Sink, A.T. Shulgin, P.F. Daley, S.D. Brandt, R.B. Rothman, A.E. Ruoho, and N.V. Cozzi The designer methcathinone analogs, mephedrone and methylone, are substrates for monoamine transporters in brain tissue Neuropsychopharmacology 37 2012 1192 1203
5. M.H. Baumann, R.D. Clark, W.L. Woolverton, S. Wee, B.E. Blough, and R.B. Rothman In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat J. Pharmacol. Exp. Ther. 337 2011 218 225
6. M.H. Baumann, J.S. Partilla, K.R. Lehner, E.B. Thorndike, A.F. Hoffman, M. Holy, R.B. Rothman, S.R. Goldberg, C.R. Lupica, H.H. Sitte, S.D. Brandt, S.R. Tella, N.V. Cozzi, and C.W. Schindler Powerful cocaine-like actions of 3,4-Methylenedioxypyrovalerone (MDPV), a principal constituent of psychoactive 'bath salts' products Neuropsychopharmacology 38 2013 552 562
7. H.A. Borek, and C.P. Holstege Hyperthermia and multiorgan failure after abuse of "bath salts" containing 3,4-methylenedioxypyrovalerone Ann. Emerg. Med. 60 2012 103 105
8. C. Boulanger-Gobeil, M. St-Onge, M. Laliberte, and P.L. Auger Seizures and hyponatremia related to ethcathinone and methylone poisoning J. Med. Toxicol. 8 2012 59 61
9. S.D. Brandt, S. Freeman, H.R. Sumnall, F. Measham, and J. Cole Analysis of NRG 'legal highs' in the UK: identification and formation of novel cathinones Drug Test Anal. 3 2011 569 575
10. S.D. Brandt, H.R. Sumnall, F. Measham, and J. Cole Analyses of second-generation 'legal highs' in the UK: initial findings Drug Test Anal. 2 2010 377 382
11. T.M. Brunt, M.W. Koeter, R.J. Niesink, and W. van den Brink Linking the pharmacological content of ecstasy tablets to the subjective experiences of drug users Psychopharmacology (Berl) 220 2012 751 762
12. P.D. Callaghan, R.J. Irvine, and L.C. Daws Differences in the in vivo dynamics of neurotransmitter release and serotonin uptake after acute para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine revealed by chronoamperometry Neurochem. Int. 47 2005 350 361
13. K.N. Cameron, R. Kolanos, E. Solis Jr., R.A. Glennon, and L.J. De Felice Bath salts components mephedrone and methylenedioxypyrovalerone (MDPV) act synergistically at the human dopamine transporter Br. J. Pharmacol. 168 2013 1750 1757
14. H. Carmo, F. Remiao, F. Carvalho, E. Fernandes, D. de Boer, L.A. dos Reys, and M. de Lourdes Bastos 4-Methylthioamphetamine-induced hyperthermia in mice: influence of serotonergic and catecholaminergic pathways Toxicol. Appl. Pharmacol. 190 2003 262 271
15. N.V. Cozzi, S.D. Brandt, P.F. Daley, J.S. Partilla, R.B. Rothman, A. Tulzer, H.H. Sitte, and M.H. Baumann Pharmacological examination of trifluoromethyl ring-substituted methcathinone analogs Eur. J. Pharmacol. 699 2013 180 187
16. N.V. Cozzi, and K.F. Foley Methcathinone is a substrate for the serotonin uptake transporter Pharmacol. Toxicol. 93 2003 219 225
17. T.A. Dal Cason, R. Young, and R.A. Glennon Cathinone: an investigation of several N-alkyl and methylenedioxy-substituted analogs Pharmacol. Biochem. Behav. 58 1997 1109 1116
18. L.C. Daws, R.J. Irvine, P.D. Callaghan, N.P. Toop, J.M. White, and F. Bochner Differential behavioural and neurochemical effects of para-methoxyamphetamine and 3,4-methylenedioxymethamphetamine in the rat Prog. Neuro-psychopharmacol. Biol. Psychiatry 24 2000 955 977
19. E.A. De Letter, V.A. Coopman, J.A. Cordonnier, and M.H. Piette One fatal and seven non-fatal cases of 4-methylthioamphetamine (4-MTA) intoxication: clinico-pathological findings Int. J. Legal Med. 114 2001 352 356
20. B. Di Cara, R. Maggio, G. Aloisi, J.M. Rivet, E.G. Lundius, T. Yoshitake, P. Svenningsson, M. Brocco, A. Gobert, L. De Groote, L. Cistarelli, S. Veiga, C. De Montrion, M. Rodriguez, J.P. Galizzi, B.P. Lockhart, F. Coge, J.A. Boutin, P. Vayer, P.M. Verdouw, L. Groenink, and M.J. Millan Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA) J. Neurosci. 31 2011 16928 16940
21. 2B receptors are required for 3,4-methylenedioxymethamphetamine-induced hyperlocomotion and 5-HT release in vivo and in vitro J. Neurosci. 28 2008 2933 2940
22. M. Dukat, R. Young, and R.A. Glennon Effect of PMA optical isomers and 4-MTA in PMMA-trained rats Pharmacol. Biochem. Behav. 72 2002 299 305
23. EMCDDA European Drug Report 2013 2013 European Monitoring Center for Drugs and Drug Addiction (EMCDDA) www.emcdda.europa.eu
24. A.J. Eshleman, K.M. Wolfrum, M.G. Hatfield, R.A. Johnson, K.V. Murphy, and A. Janowsky Substituted methcathinones differ in transporter and receptor interactions Biochem. Pharmacol. 85 2013 1803 1815
25. R.A. Glennon, R. Young, M. Dukat, J. Chang-Fong, and M. El-Zahabi N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-methyl-1-(3,4- methylenedioxyphenyl)-2-aminopropane (MDMA) produce non-identical discriminative stimuli in rats Pharmacol. Biochem. Behav. 86 2007 477 484
26. M. Gobbi, M. Funicello, K. Gerstbrein, M. Holy, P.R. Moya, R. Sotomayor, M.I. Forray, K. Gysling, S. Paluzzi, G. Bonanno, M. Reyes-Parada, H.H. Sitte, and T. Mennini N,N-dimethyl-thioamphetamine and methyl-thioamphetamine, two non-neurotoxic substrates of 5-HT transporters, have scant in vitro efficacy for the induction of transporter-mediated 5-HT release and currents J. Neurochem. 105 2008 1770 1780
27. B. Gough, S.Z. Imam, B. Blough, W. Slikker Jr., and S.F. Ali Comparative effects of substituted amphetamines (PMA, MDMA, and METH) on monoamines in rat caudate: a microdialysis study Ann. N. Y. Acad. Sci. 965 2002 410 420
28. A.L. Green, and M.A. El Hait p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo J. Pharm. Pharmacol. 32 1980 262 266
29. G.C. Hadlock, K.M. Webb, L.M. McFadden, P.W. Chu, J.D. Ellis, S.C. Allen, D.M. Andrenyak, P.L. Vieira-Brock, C.L. German, K.M. Conrad, A.J. Hoonakker, J.W. Gibb, D.G. Wilkins, G.R. Hanson, and A.E. Fleckenstein 4- Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse J. Pharmacol. Exp. Ther. 339 2011 530 536
30. X. Huang, D. Marona-Lewicka, and D.E. Nichols p-methylthioamphetamine is a potent new non-neurotoxic serotonin-releasing agent Eur. J. Pharmacol. 229 1992 31 38
31. C.M. Hysek, L.D. Simmler, V. Nicola, N. Vischer, M. Donzelli, S. Krähenbühl, E. Grouzmann, M.C. Hoener, and M.E. Liechti Duloxetine inhibits effects of MDMA ("ecstasy") in vitro and in humans in a randomized placebo-controlled laboratory study PLoS One 7 2012 e36476
32. L. Iversen, S. Gibbons, R. Treble, V. Setola, X.P. Huang, and B.L. Roth Neurochemical profiles of some novel psychoactive substances Eur. J. Pharmacol. 700 2013 147 151
33. D. James, R.D. Adams, R. Spears, G. Cooper, D.J. Lupton, J.P. Thompson, and S.H. Thomas Clinical characteristics of mephedrone toxicity reported to the U.K. National Poisons Information Service Emerg. Med. J. 28 2011 686 689
34. S.S. Johansen, A.C. Hansen, I.B. Muller, J.B. Lundemose, and M.B. Franzmann Three fatal cases of PMA and PMMA poisoning in Denmark J. Anal. Toxicol. 27 2003 253 256
35. J. Kehr, F. Ichinose, S. Yoshitake, M. Goiny, T. Sievertsson, F. Nyberg, and T. Yoshitake Mephedrone, compared to MDMA (ecstasy) and amphetamine, rapidly increases both dopamine and serotonin levels in nucleus accumbens of awake rats Br. J. Pharmacol. 164 2011 1949 1958
36. R. Lopez-Arnau, J. Martinez-Clemente, D. Pubill, E. Escubedo, and J. Camarasa Comparative neuropharmacology of three psychostimulant cathinone derivatives: butylone, mephedrone and methylone Br. J. Pharmacol. 167 2012 407 420
37. Y. Lurie, A. Gopher, O. Lavon, S. Almog, L. Sulimani, and Y. Bentur Severe paramethoxymethamphetamine (PMMA) and paramethoxyamphetamine (PMA) outbreak in Israel Clin. Toxicol. 50 2012 39 43
38. C.R. Maheux, and C.R. Copeland Chemical analysis of two new designer drugs: buphedrone and pentedrone Drug Test Anal. 4 2012 17 23
39. L.J. Marinetti, and H.M. Antonides Analysis of synthetic cathinones commonly found in bath salts in human performance and postmortem toxicology: method development, drug distribution and interpretation of results J. Anal. Toxicol. 37 2013 135 146
40. J.A. Marusich, K.R. Grant, B.E. Blough, and J.L. Wiley Effects of synthetic cathinones contained in "bath salts" on motor behavior and a functional observational battery in mice Neurotoxicology 33 2012 1305 1313
41. K. Moore, P.I. Dargan, D.M. Wood, and F. Measham Do novel psychoactive substances displace established club drugs, supplement them or act as drugs of initiation? The relationship between mephedrone, ecstasy and cocaine Eur. Addict. Res. 19 2013 276 282
42. D.E. Nichols Hallucinogens Pharmacol. Ther. 101 2004 131 181
43. J.M. Prosser, and L.S. Nelson The toxicology of bath salts: a review of synthetic cathinones J. Med. Toxicol. 8 2012 33 42
44. S.T. Quinn, P.J. Guiry, T. Schwab, A.K. Keenan, and G.J. McBean Blockade of noradrenaline transport abolishes 4-methylthioamphetamine-induced contraction of the rat aorta in vitro Auton. Autacoid Pharmacol. 26 2006 335 344
45. S. Refstad Paramethoxyamphetamine (PMA) poisoning; a 'party drug' with lethal effects Acta Anaesthesiol. Scand. 47 2003 1298 1299
46. 1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity Proc. Natl. Acad. Sci. U. S. A. 108 2011 8485 8490
47. R. Rosenauer, A. Luf, M. Holy, M. Freissmuth, R. Schmid, and H.H. Sitte A combined approach using transporter-flux assays and mass spectrometry to examine psychostimulant street drugs of unknown content ACS Chem. Neurosci. 4 2013 182 190
48. B.L. Roth Drugs and valvular heart disease N. Engl. J. Med. 356 2007 6 9
49. R.B. Rothman, and M.H. Baumann Balance between dopamine and serotonin release modulates behavioral effects of amphetamine-type drugs Ann. N. Y. Acad. Sci. 1074 2006 245 260
50. G. Rudnick, and S.C. Wall The molecular mechanism of "ecstasy" [3,4-methylenedioxy-methamphetamine (MDMA)]: serotonin transporters are targets for MDMA-induced serotonin release Proc. Natl. Acad. Sci. U. S. A. 89 1992 1817 1821
51. P. Scholze, J. Zwach, A. Kattinger, C. Pifl, E.A. Singer, and H.H. Sitte Transporter-mediated release: a superfusion study on human embryonic kidney cells stably expressing the human serotonin transporter J. Pharmacol. Exp. Ther. 293 2000 870 878
52. L. Simmler, T. Buser, M. Donzelli, Y. Schramm, L.H. Dieu, J. Huwyler, S. Chaboz, M. Hoener, and M.E. Liechti Pharmacological characterization of designer cathinones in vitro Br. J. Pharmacol. 168 2013 458 470
53. R. Sotomayor-Zarate, G. Quiroz, K.A. Araya, J. Abarca, M.R. Ibanez, A. Montecinos, C. Guajardo, G. Nunez, A. Fierro, P.R. Moya, P. Iturriaga-Vasquez, C. Gomez-Molina, K. Gysling, and M. Reyes-Parada 4-Methylthioamphetamine increases dopamine in the rat striatum and has rewarding effects in vivo Basic Clin. Pharmacol. Toxicol. 111 2012 371 379
54. T. Steinkellner, M. Freissmuth, H.H. Sitte, and T. Montgomery The ugly side of amphetamines: short- and long-term toxicity of 3,4- methylenedioxymethamphetamine (MDMA, 'Ecstasy'), methamphetamine and D-amphetamine Biol. Chem. 392 2011 103 115
55. M. Tatsumi, K. Groshan, R.D. Blakely, and E. Richelson Pharmacological profile of antidepressants and related compounds at human monoamine transporters Eur. J. Pharmacol. 340 1997 249 258
56. R.E. Tessel, and C.O. Rutledge Specificity of release of biogenic amines from isolated rat brain tissue as a function of the meta substituent of N-ethylamphetamine derivatives J. Pharmacol. Exp. Ther. 197 1976 253 262
57. C.D. Verrico, G.M. Miller, and B.K. Madras MDMA (ecstasy) and human dopamine, norepinephrine, and serotonin transporters: implications for MDMA-induced neurotoxicity and treatment Psychopharmacology 189 2007 489 503
58. M. Vevelstad, E.L. Oiestad, G. Middelkoop, I. Hasvold, P. Lilleng, G.J. Delaveris, T. Eggen, J. Morland, and M. Arnestad The PMMA epidemic in Norway: comparison of fatal and non-fatal intoxications Forens. Sci. Int. 219 2012 151 157
59. L.R. Watterson, P.R. Kufahl, N.E. Nemirovsky, K. Sewalia, M. Grabenauer, B.F. Thomas, J.A. Marusich, S. Wegner, and M.F. Olive Potent rewarding and reinforcing effects of the synthetic cathinone 3,4-methylenedioxypyrovalerone (MDPV) Addict. Biol. 2012 (in press) http://dx.doi.org/10.1111/j.1369-1600.2012. 00474.x
60. S. Wee, K.G. Anderson, M.H. Baumann, R.B. Rothman, B.E. Blough, and W.L. Woolverton Relationship between the serotonergic activity and reinforcing effects of a series of amphetamine analogs J. Pharmacol. Exp. Ther. 313 2005 848 854
61. F. Westphal, T. Junge, U. Girreser, W. Greibl, and C. Doering Mass, NMR and IR spectroscopic characterization of pentedrone and pentylone and identification of their isocathinone by-products Forens. Sci. Int. 217 2012 157 167
62. M. Wikstrom, G. Thelander, I. Nystrom, and R. Kronstrand Two fatal intoxications with the new designer drug methedrone (4-methoxymethcathinone) J. Anal. Toxicol. 34 2010 594 598
63. A.R. Winstock, K. Wolff, and J. Ramsey 4-MTA: a new synthetic drug on the dance scene Drug Alcohol Depend. 67 2002 111 115
64. H. Yu, R.B. Rothman, C.M. Dersch, J.S. Partilla, and K.C. Rice Uptake and release effects of diethylpropion and its metabolites with biogenic amine transporters Bioorg. Med. Chem. 8 2000 2689 2692
65. D. Zuba, P. Adamowicz, and B. Byrska Detection of buphedrone in biological and non-biological material-two case reports Forens. Sci. Int. 227 2013 15 20
66. D. Zuba, and B. Byrska Prevalence and co-existence of active components of 'legal highs' Drug Test Anal. 5 2013 420 429